CetuGEX™ in Comparison to Cetuximab for the Treatment of Patients With Head and Neck Cancer
NCT ID: NCT02052960
Last Updated: 2021-11-02
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
240 participants
INTERVENTIONAL
2014-02-28
2017-10-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Primary Objective:
To evaluate the efficacy of CetuGEX™ for the treatment of patients with stage III/IV recurrent and/or metastatic SCCHN as compared to cetuximab (both in combination with platinum-based chemotherapy) in terms of progression-free survival (PFS).
Secondary Objectives:
To evaluate further efficacy criteria, safety and quality of life (QoL) of patients with stage III/IV recurrent and/or metastatic SCCHN treated with CetuGEX™ as compared to cetuximab (both in combination with platinum-based chemotherapy).
To assess pharmacokinetic (PK) parameters and profiles of CetuGEX™. To assess efficacy and safety based on genetic markers for immune response (Fc-gamma receptor \[FcγR\] allotypes) and biomarkers (exploratory only).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CetuGEX™ plus chemotherapy
720 mg weekly administration
CetuGEX™
60 mg/day 0, 930 mg/day 1, followed by 720 mg i.v. weekly administration
Chemotherapy
Combination of Cisplatin and 5-Fluorouracil (Carboplatin may substitute Cisplatin following the 1st cycle of therapy in case of toxicity)
Cetuximab plus chemotherapy
250 mg/m2 weekly administration
Cetuximab
400 mg/sqm body surface area (BSA) on day 1, followed by 250 mg/sqm BSA i.v. weekly administration
Chemotherapy
Combination of Cisplatin and 5-Fluorouracil (Carboplatin may substitute Cisplatin following the 1st cycle of therapy in case of toxicity)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CetuGEX™
60 mg/day 0, 930 mg/day 1, followed by 720 mg i.v. weekly administration
Cetuximab
400 mg/sqm body surface area (BSA) on day 1, followed by 250 mg/sqm BSA i.v. weekly administration
Chemotherapy
Combination of Cisplatin and 5-Fluorouracil (Carboplatin may substitute Cisplatin following the 1st cycle of therapy in case of toxicity)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients with measurable disease according to RECIST 1.1.
3. Patients aged at least 18 years at screening.
4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
5. Minimum life expectancy of 3 months.
6. Tissue samples available for specific and therapy-related biological assessments.
7. If female and of childbearing potential, was non-lactating and had negative pregnancy test results at screening and prior to randomization.
8. If female, was either not of childbearing potential (defined as postmenopausal for at least 1 year or surgically sterile \[bilateral tubal ligation, bilateral oophorectomy, or hysterectomy\]) or willing to use highly effective contraceptives during study participation until 6 months after last administration of any study medication, particularly cisplatin or carboplatin, with a failure rate \<1% according to the Note for Guidance on non-clinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals (CPMP/ICH/286/95) of the European Medicines Agency. Male patients who had partners of childbearing potential had to confirm adequate use of highly effective contraceptives during study participation until 6 months after last administration of any study medication, particularly cisplatin or carboplatin, as well.
9. Willing and able to comply with the protocol.
10. Willing and able to provide written informed consent.
Exclusion Criteria
2. Cetuximab or other epidermal growth factor receptor (EGFR)-targeting agent treatment, except if given as part of a multimodal treatment for locally advanced disease which was completed more than 6 months prior to randomization.
3. Surgery (other than minor interventions like diagnostic biopsy or intravenous port implantation) or irradiation within 30 days before randomization.
4. Concomitant antitumor therapy or concomitant immunotherapy, live vaccines including yellow fever vaccination (as per cisplatinum Summary of Product Characteristics \[SmPC\]).
5. Concomitant corticosteroid treatment unless specified within the protocol.
6. Clinical evidence of brain metastasis or leptomeningeal involvement.
7. Patients with nasopharyngeal tumors.
8. Concomitant malignant disease, except for adequately treated tumors with high likelihood of being cured (e.g., basal cell cancer of the skin, cervical cancer or breast cancer in situ). Patients with previous malignancies but without evidence of disease for at least 5 years were allowed to enter the study.
9. Patients with renal or hepatic impairment (serum creatinine and bilirubin \>1.5 fold above the upper limit of normal ranges, creatinine clearance \<60 mL/min, and transaminase \>5-fold above the upper limit of normal ranges) and patients with hematology parameters outside the normal ranges (hemoglobin \<9 g/dL, absolute neutrophil count \<1500/mm3 and platelet count \<105/mm3) at screening as well as patients with impaired auditory function or platinum-related neuropathy.
10. Clinically active infections ≥Grade 2 using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4 and/or requiring intravenous antibiotics.
11. Known active hepatitis B or C.
12. Known human immunodeficiency virus (HIV) infection.
13. Myocardial infarction within 6 months prior to screening.
14. Symptomatic congestive heart failure (New York Heart Association Grade 3 or 4), unstable angina pectoris within 6 months prior to screening, significant cardiac arrhythmia, history of stroke, or transient ischemic attack within 1 year prior to screening.
15. History of keratitis requiring medical interventions within the last 5 years or interstitial lung disease.
16. Patients with any other disorder that, in the opinion of the investigator, might have interfered with the conduct of the study.
17. Patients with an unstable condition (e.g., psychiatric disorder, a recent history of drug or alcohol abuse, interfering with study compliance, within 6 months prior to screening) or otherwise thought to be unreliable or incapable of complying with the requirements of the protocol.
18. Patients institutionalized by official means or court order.
19. Receipt of any other IMP within the last 30 days before randomization or any previous CetuGEX™ administration.
20. Prior allergic reaction to a monoclonal antibody, grade 3 infusion related reaction (IRR) or any grade 4 reaction to a monoclonal antibody.
21. Known sensitivity to any component of the IMP and medication used in this study.
22. Known dihydropyrimidine dehydrogenase deficiency (France only).
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Glycotope GmbH
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ulrich Keilholz, Prof
Role: PRINCIPAL_INVESTIGATOR
Charite University, Berlin, Germany
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Glycotope-contracted Research Facility
Antwerp, , Belgium
Glycotope-contracted Research Facility
Brussels, , Belgium
Glycotope-contracted Research Facility
Brussels, , Belgium
Glycotope-contracted Research Facility
Ghent, , Belgium
Glycotope-contracted Research Facility
Avignon, , France
Glycotope-contracted Research Facility
Lille, , France
Glycotope-contracted Research Facility
Lyon, , France
Glycotope-contracted Research Facility
Nice, , France
Glycotope-contracted Research Facility
Saint-Herblain, , France
Glycotope-contracted Research Facility
Aachen, , Germany
Glycotope-contracted Research Facility
Berlin, , Germany
Glycotope-contracted Research Facility
Dresden, , Germany
Glycotope-contracted Research Facility
Essen, , Germany
Glycotope-contracted Research Facility
Hamburg, , Germany
Glycotope-contracted Research Facillity
Hanover, , Germany
Glycotope-contracted Research Facility
Leipzig, , Germany
Gycotope-contracted Research Facility
Milan, , Italy
Glycotope-contracted Research Facility
Pavia, , Italy
Glycotope-contracted Research Facility
Bydgoszcz, , Poland
Glycotope-contracted Research Facility
Krakow, , Poland
Glycotope-contracted Research Facility
Lodz, , Poland
Glycotope-contracted Research Facility
Lublin, , Poland
Glycotope-contracted Research Facility
Warsaw, , Poland
Glycotope-contracted Research Facility
Brasov, , Romania
Glycotope-contracted Research Facility
Clui-Napoca, , Romania
Glycotope-contracted Research Facility
Craiova, , Romania
Glycotope-contracted Research Facility
Oradea, , Romania
Glycotope-contracted Research Facility
Ploieşti, , Romania
Glycotope-contracted Research Facility
Timișoara, , Romania
Glycotope-contracteed Research Facility
Timișoara, , Romania
Glycotope-contracted Research Facility
Barcelona, , Spain
Glycotope-contracted Research Facility
Madrid, , Spain
Glycotope-contracted Research Facility
Madrid, , Spain
Glycotope-contracted Research Facility
Valencia, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2013-000931-28
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
GEXMab52201
Identifier Type: -
Identifier Source: org_study_id